Synergy CHC Corp. Reports Termination of $2.9M Brand License Agreement
SNYR is trading near its 52-week low of $1.27 (4.7% above the low).
Summary
Synergy CHC Corp. announced the termination of its Brand License Agreement with Gravity Pharma, which involved a $2.9 million license fee for FOCUSfactor and Flat Tummy Co. products in the UAE and Turkey.
Key Events · Legal and Risk Events · SNYR
-
Brand License Agreement Terminated
Gravity Pharma General Trading LLC terminated the Brand License Agreement, dated March 31, 2025, for FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey.
-
Significant Revenue Impact
The agreement was for an aggregate license fee of $2.9 million, which Synergy CHC Corp. had previously accounted for as revenue. The termination is 'ab initio', implying a potential reversal of this revenue.
-
Company Continues Market Pursuit
Despite the termination, the company stated it continues to pursue the registration and marketing of the licensed intellectual property in the affected territories.
Analysis · SNYR · Life Sciences
The termination of a $2.9 million brand license agreement, previously recognized as revenue, represents a significant financial setback for Synergy CHC Corp., especially given its approximate $15 million market capitalization. The 'ab initio' nature of the termination suggests a potential reversal of this revenue, which could materially impact the company's financial statements. This event, occurring while the stock trades near its 52-week low, underscores challenges in the company's international expansion strategy and could exert further downward pressure on the stock price.
At the time of this filing, SNYR was trading at $1.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15M. The 52-week trading range was $1.27 to $4.08. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.